Articles Referencing PPHM
Encouraging News for Peregrine Pharma - Analyst Blog
5/24/2013, 12:28 pm from Zacks.com in Investing, Business, Stocks
Peregrine Pharmaceuticals ( PPHM ) recently
received encouraging news when the company announced that the US
Food and Drug Administration (FDA) has agreed on the design for the
phase III... Read >>
Encouraging News for Peregrine Pharma - Analyst Blog
5/23/2013, 7:26 pm from Zacks.com in Investing, Business, Stocks
Peregrine Pharmaceuticals ( PPHM ) recently
received encouraging news when the company announced that the US
Food and Drug Administration (FDA) has agreed on the design for the
phase III... Read >>
Osiris Loss In-Line with Expectations - Analyst Blog
5/8/2013, 6:24 pm from Zacks.com in Investing, Business, Stocks
Osiris Loss In-Line with Expectations Osiris Therapeutics Inc. ( OSIR ) reported a
first-quarter 2013 loss of 8 cents per share, in-line with the
Zacks Consensus Estimate but wider than... Read >>
Peregrine Reports Narrower Loss - Analyst Blog
3/13/2013, 6:14 pm from Zacks.com in Investing, Business, Stocks
Peregrine Pharmaceuticals, Inc. ( PPHM ) reported a net
loss of 4 cents per share in the third quarter of fiscal 2013
(ended Jan 31, 2013), narrower than the year-ago loss of 13 cents
and... Read >>
Update on Peregrine's Bavituximab - Analyst Blog
2/20/2013, 1:50 pm from Zacks.com in Investing, Business, Stocks
Peregrine Pharmaceuticals, Inc. ( PPHM ) recently
announced updated data on bavituximab from its randomized,
double-blind placebo-controlled phase II trial that was conducted
in patients... Read >>
Data on Peregrine's Bavituximab - Analyst Blog
2/14/2013, 4:00 pm from Zacks.com in Investing, Business, Stocks
Peregrine Pharmaceuticals ( PPHM ) recently
announced phase II data on its oncology candidate, bavituximab. The
open-label, randomized phase II study was conducted in patients
suffering... Read >>
Priority FDA Review for Celgene Drug - Analyst Blog
2/12/2013, 4:40 pm from Zacks.com in Investing, Business, Stocks
Recently, Celgene Corporation ( CELG ) announced that
the US Food and Drug Administration (FDA) will review the
supplemental New Drug Application (sNDA) for cancer drug... Read >>
Gilead Closes YM Biosciences Buyout - Analyst Blog
2/11/2013, 6:13 pm from Zacks.com in Investing, Business, Stocks
Recently, Gilead Sciences, Inc. ( GILD ) completed its
acquisition of Canada-based drug development company, YM
BioSciences Inc. for $2.95 per share. Through this acquisition,
Gilead aims... Read >>
Protalix Exploring Options - Analyst Blog
2/7/2013, 6:15 pm from Zacks.com in Investing, Business, Stocks
Protalix BioTherapeutics, Inc. ( PLX ) recently
confirmed that it has hired Citigroup, Inc. ( C ) to explore strategic
options. Protalix, an Israel-based biopharmaceutical... Read >>
Pipeline Setback for Idenix - Analyst Blog
2/7/2013, 5:10 pm from Zacks.com in Investing, Business, Stocks
Idenix Pharmaceuticals, Inc. ( IDIX ) recently
announced that the company has decided to discontinue its clinical
development program for IDX184.
IDX184 is a nucleotide polymerase... Read >>
Medivation's Xtandi Impresses - Analyst Blog
2/7/2013, 4:30 pm from Zacks.com in Investing, Business, Stocks
Medivation, Inc. ( MDVN ) recently
announced that its partner Astellas Pharma Inc. (
ALPMY ) reported
Xtandi (enzalutamide) sales of about $57 million in the US for the
quarter ended... Read >>
Vivus Unveils Qsymia Study Results - Analyst Blog
2/7/2013, 1:40 pm from Zacks.com in Investing, Business, Stocks
Vivus Inc. ( VVUS ) recently
announced the publication of results from a study regarding its
weight-loss drug, Qsymia. Results from the study revealed that the
weight loss arising from... Read >>
Gilead Beats Estimates in 4Q - Analyst Blog
2/5/2013, 9:30 am from Zacks.com in Investing, Business, Stocks
Gilead Sciences, Inc. 's ( GILD ) fourth quarter
2012 earnings (excluding special items but including stock option
expense) of 47 cents per share beat the Zacks Consensus Estimate of
45... Read >>
Canada Approves Seattle Genetics' Adcetris - Analyst Blog
2/4/2013, 5:44 pm from Zacks.com in Investing, Business, Stocks
Seattle Genetics Inc. ( SGEN ) recently
received approval from Health Canada for its oncology drug,
Adcetris (brentuximab vedotin). Adcetris has been approved under
Health Canada's Notice... Read >>
Alnylam Prices Public Offering - Analyst Blog
1/16/2013, 4:40 pm from Zacks.com in Investing, Business, Stocks
Alnylam Pharmaceuticals Inc. ( ALNY ) provided
pricing and other details regarding its recently announced public
offering of shares of its common stock. Alnylam is offering 8
million shares... Read >>